256 related articles for article (PubMed ID: 10726056)
21. Small animal model systems for studying hepatitis B virus replication and pathogenesis.
Dandri M; Lutgehetmann M; Volz T; Petersen J
Semin Liver Dis; 2006 May; 26(2):181-91. PubMed ID: 16673296
[TBL] [Abstract][Full Text] [Related]
22. High persistence rate of hepatitis B virus in a hydrodynamic injection-based transfection model in C3H/HeN mice.
Peng XH; Ren XN; Chen LX; Shi BS; Xu CH; Fang Z; Liu X; Chen JL; Zhang XN; Hu YW; Zhou XH
World J Gastroenterol; 2015 Mar; 21(12):3527-36. PubMed ID: 25834317
[TBL] [Abstract][Full Text] [Related]
23. [Advance in clinical studies of the kinetics of hepatitis B virus].
Tang YT; Cao Q; Zhang DZ
Zhonghua Gan Zang Bing Za Zhi; 2010 Jan; 18(1):75-7. PubMed ID: 20128981
[No Abstract] [Full Text] [Related]
24. The short hairpin RNA driven by polymerase II suppresses both wild-type and lamivudine-resistant hepatitis B virus strains.
Ren GL; Fang Y; Ma HH; Lei YF; Wang D; Xu MC; Wang PZ; Huang CX; Nie OH; Sun YT; Bai XF
Antivir Ther; 2007; 12(6):865-76. PubMed ID: 17926641
[TBL] [Abstract][Full Text] [Related]
25. Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping.
Ohishi W; Shirakawa H; Kawakami Y; Kimura S; Kamiyasu M; Tazuma S; Nakanishi T; Chayama K
J Med Virol; 2004 Apr; 72(4):558-65. PubMed ID: 14981758
[TBL] [Abstract][Full Text] [Related]
26. Whole genome expression profiling of hepatitis B virus-transfected cell line reveals the potential targets of anti-HBV drugs.
Ding XR; Yang J; Sun DC; Lou SK; Wang SQ
Pharmacogenomics J; 2008 Feb; 8(1):61-70. PubMed ID: 17505500
[TBL] [Abstract][Full Text] [Related]
27. [Development of a hepatitis B virus carrier transgenic mice model].
Caner M; Arat S; Bircan R
Mikrobiyol Bul; 2008 Jan; 42(1):71-81. PubMed ID: 18444564
[TBL] [Abstract][Full Text] [Related]
28. [Comparison of different combination therapies for children with HBeAg positive chronic hepatitis B].
Zhong XH; Deng X; Chen XC; Zhou BP
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Mar; 21(1):62-3. PubMed ID: 17429539
[TBL] [Abstract][Full Text] [Related]
29. Response to antiviral treatment in patients infected with hepatitis B virus genotypes E-H.
Erhardt A; Göbel T; Ludwig A; Lau GK; Marcellin P; van Bömmel F; Heinzel-Pleines U; Adams O; Häussinger D
J Med Virol; 2009 Oct; 81(10):1716-20. PubMed ID: 19697400
[TBL] [Abstract][Full Text] [Related]
30. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers.
Kohmoto M; Enomoto M; Tamori A; Habu D; Takeda T; Kawada N; Sakaguchi H; Seki S; Shiomi S; Nishiguchi S
J Med Virol; 2005 Feb; 75(2):235-9. PubMed ID: 15602726
[TBL] [Abstract][Full Text] [Related]
31. Individualization of interferon therapy using serum hepatitis B virus DNA to reduce viral relapse in patients with chronic hepatitis B: a randomized controlled trial.
Chung YH; Song BC; Lee GC; Shin JW; Ryu SH; Jung SA; Yoo K; Lee HC; Lee YS; Suh DJ
Eur J Gastroenterol Hepatol; 2003 May; 15(5):489-93. PubMed ID: 12702905
[TBL] [Abstract][Full Text] [Related]
32. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.
Lai CL; Rosmawati M; Lao J; Van Vlierberghe H; Anderson FH; Thomas N; Dehertogh D
Gastroenterology; 2002 Dec; 123(6):1831-8. PubMed ID: 12454840
[TBL] [Abstract][Full Text] [Related]
33. Sequential control of hepatitis B virus in a mouse model of acute, self-resolving hepatitis B.
von Freyend MJ; Untergasser A; Arzberger S; Oberwinkler H; Drebber U; Schirmacher P; Protzer U
J Viral Hepat; 2011 Mar; 18(3):216-26. PubMed ID: 20367794
[TBL] [Abstract][Full Text] [Related]
34. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
Suzuki F; Akuta N; Suzuki Y; Sezaki H; Arase Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Watahiki S; Kumada H
J Med Virol; 2006 Mar; 78(3):341-52. PubMed ID: 16419116
[TBL] [Abstract][Full Text] [Related]
35. Human MxA protein participates to the interferon-related inhibition of hepatitis B virus replication in female transgenic mice.
Peltekian C; Gordien E; Garreau F; Meas-Yedid V; Soussan P; Willams V; Chaix ML; Olivo-Marin JC; Bréchot C; Kremsdorf D
J Hepatol; 2005 Dec; 43(6):965-72. PubMed ID: 16168514
[TBL] [Abstract][Full Text] [Related]
36. [Clinical study of lamivudine and interferon combinate administration to inhibit hepatitis B virus replication].
Song JW; Zhang G; Lin JG; Tang WX; Lin JS
Zhonghua Gan Zang Bing Za Zhi; 2004 Oct; 12(10):593-6. PubMed ID: 15504288
[TBL] [Abstract][Full Text] [Related]
37. In vitro resistance to interferon-alpha of hepatitis B virus with basic core promoter double mutation.
Wang Y; Wei L; Jiang D; Cong X; Fei R; Chen H; Xiao J; Wang Y
Antiviral Res; 2007 Aug; 75(2):139-45. PubMed ID: 17397939
[TBL] [Abstract][Full Text] [Related]
38. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus.
Tsuge M; Hiraga N; Takaishi H; Noguchi C; Oga H; Imamura M; Takahashi S; Iwao E; Fujimoto Y; Ochi H; Chayama K; Tateno C; Yoshizato K
Hepatology; 2005 Nov; 42(5):1046-54. PubMed ID: 16250045
[TBL] [Abstract][Full Text] [Related]
39. Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy.
Shin JW; Chung YH; Choi MH; Kim JA; Ryu SH; Jang MK; Kim IS; Park NH; Lee HC; Lee YS; Suh DJ
J Gastroenterol Hepatol; 2005 Jun; 20(6):844-9. PubMed ID: 15946130
[TBL] [Abstract][Full Text] [Related]
40. Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan.
Suzuki Y; Kobayashi M; Ikeda K; Suzuki F; Arfase Y; Akuta N; Hosaka T; Saitoh S; Kobayashi M; Someya T; Matsuda M; Sato J; Watabiki S; Miyakawa Y; Kumada H
J Med Virol; 2005 May; 76(1):33-9. PubMed ID: 15779048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
